Eric L. Simpson’s research while affiliated with Oregon Health & Science University and other places

... Furthermore, Phase 2b data on orismilast in psoriasis (IASOS) indicated a deeper response for this indication compared to apremilast based on the proportion of patients achieving PASI90 (orismilast 20 mg: 24.1%; 30 mg: 22.0%; 40 mg: 28.3%; placebo: 8.3%; p < 0.05 for 20 and 40 mg doses), which is numerically greater than for apremilast (30 mg: 9.8% vs placebo: 0.4%, p < 0·05) [7]. Recently, we reported clinical data on orismilast from a 16-week Phase 2b study in patients with AD, and although not all endpoints reached statistical significance, more patients achieved an Investigator's Global Assessment (IGA) of 0/1 at Week 16 in the orismilast groups compared to placebo (orismilast 20 mg: 26.3%; 30 mg: 24.3%; 40 mg: 30.9%; placebo: 9.5%; p < 0.05 for 20 and 40 mg doses) [8]. These data suggest that the clinical relevance of selective PDE4B/D inhibition with orismilast has potential to offer a convenient, novel oral therapy to treat psoriasis and AD. ...

Reference:

Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis

... Once-daily roflumilast cream 0.05% significantly improved AD signs and symptoms in pediatric patients aged 2-5 years, with significant improvement in vIGA-AD observed as early as the first timepoint (1 week after treatment initiation) and improvement in pruritus within the first 24 h. [19]. Therefore, a longer duration of treatment in patients aged 2-5 years may lead to a greater EASI-75 response, similar to that observed in patients aged ≥ 6 years who participated in the INTEGUMENT-OLE trial. ...

Reference:

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial

... In recent years, biologics and JAK inhibitors have emerged as key systemic therapies to control flares and potentially reach a Minimal Disease Activity (MDA) status in individuals with moderate-tosevere AD [1]. For patients who achieve optimal outcomes with biological therapy, reducing the dosing frequency (optimization) may be a viable consideration [2,3]. This approach holds particular significance for elderly individuals (> 65 years), who are often on multiple medications and have several comorbidities [2,3]. ...

Reference:

Long-Term Efficacy and Potential Predictors of Tralokinumab Dose Optimization in Elderly Patients: A Multicentre Study

... While these 8-week trials were of relatively short duration, the subsequent long-term extension trial, ADORING 3, assessed the efficacy, safety, and tolerability of tapinarof cream in AD across the spectrum of severity, including patients with mild or more severe AD for up to 48 weeks (25). Tapinarof was effective for a diverse patient population across these trials, with an age range of 2 to 81 years (80% pediatric patients in ADORING 1 and 2) and approximately 50% with skin of color (21,25). ...

Reference:

Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials

... Improvements were obtained in a number of indicators including pruritus, sleep, skin pain and overall quality of life, which was maintained for 44 weeks of its use as needed. 16 Topical tofacitinib has undergone a 4-week randomized double-blind phase 2a study. The 2% ointment achieved satisfactory results in the treatment of AD, but side effects such as nasopharyngitis, upper respiratory tract infection are the reason for the lack of research development for this drug. ...

Reference:

Modern treatment methods in atopic dermatitis - literature overview

... 3 In GERD patients, biopsies of the distal, squamous-lined esophagus typically reveal thickening of the basal cell layer, papillary elongation, and dilated intercellular spaces. 4 However, neither the symptoms nor histologic features of GERD are specific to the disorder, and an objective diagnosis of GERD requires endoscopic evidence of Los Angeles grade B, C, or D reflux esophagitis, and/ or Barrett's esophagus with intestinal metaplasia, and/or esophageal reflux monitoring demonstrating abnormal reflux. 5 Eosinophilic esophagitis (EoE) is an allergy-mediated esophageal disease characterized clinically by symptoms of esophageal dysfunction (typically dysphagia and food impaction) and histologically by eosinophil-predominant esophageal inflammation. ...

Reference:

Can Gastroesophageal Reflux Disease without Concomitant Eosinophilic Esophagitis Cause High-level Esophageal Eosinophilia?

... In clinical trials, standardized quality-of-life questionnaires and clinical disease assessment tools showed improvements for both diseases in ages 6 to < 18 years [20][21][22][23]. Dupilumab has been associated with an improvement in symptoms and quality of life [24][25][26]. However, only a limited number of pediatric patients have been assessed in real-world observational studies outside the controlled environment of phase 3 trials [27][28][29][30][31][32]. ...

Reference:

Medication-related perceptions of children and adolescents with severe asthma and moderate-to-severe atopic dermatitis: a non-interventional exploratory study

... Recent advances in biologic therapies for AD are notable, particularly pharmacological inhibition of IL-4 and 13 signaling with dupilumab have shown outstanding clinical efficacy for patients with AD [21,22]. In addition, dupilumab has shown concomitant improvements in critical factors of moderate-to-severe AD pathogenesis, including decreased abundance of S. aureus on the skin surface [21,22]. ...

Reference:

Skin Infections in Atopic Dermatitis: Treatment Challenges

... Prolonged use of topical corticosteroids on the face is not recommended and is associated with skin atrophy, periorificial dermatitis, rebound dermatitis, acneiform changes, and rosacea (1,7,8,(11)(12)(13). Application site burning in the face is common with topical calcineurin inhibitors and phosphodiesterase-4 inhibitors (7,14,15), albeit less frequently with roflumilast (16). Thus, there is a need for additional effective and tolerable topical therapies for the treatment of facial and neck AD. ...

Reference:

Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial

... Our results confirm the data on safety observed in both clinical trials and real-life studies regarding the risk of VTEs during therapy with JAK inhibitors for moderate-to-severe AD: a recent systematic review and meta-analysis reported no significant differences between patients with AD receiving dupilumab or placebo and those on JAK inhibitor therapy, with the latter showing an overall incidence of 0.15 events per 100 patient-years [19]. Recent evidence on the safety profile related to the development of malignancies and MACE in patients with AD receiving JAK inhibitor therapy indicates a low incidence, suggesting a lower risk compared with patients with RA [20]. However, the possibility of longterm risk cannot be excluded. ...

Reference:

Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study